SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Pharmos (PARS)
An SI Board Since October 1998
Posts SubjectMarks Bans Symbol
1386 42 0 PARS
Emcee:  Dr. John M. de Castro Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1361$60 million plus in cash after BOL makes its payment. The CB-2 platform is near NeuroInvestment-12/20/2004
1360Neuro -- anything of value left here after the poor TBI results? Tomtom r. phillips-12/20/2004
1359haaretzdaily.comrjk01-12/19/2004
1358The shorts are not budging, I dont see any panic. This is going to be a long nerrjk01-12/17/2004
1357Pharmos trial the stuff of speculators' dreams By ZEV STUB Its December andmidastouch017-12/17/2004
1356Pharmos trial the stuff of speculators' dreams By ZEV STUB Its December andmidastouch017-12/17/2004
1355That's my bet in the office pool, and this is based on pure conjecture. HarNeuroInvestment-12/16/2004
1354Many predict this upcoming Mon as D-Day. rjk01-12/16/2004
1353Pharmos to receive $10m on Bausch & Lomb's FDA approval for opthalmic trmidastouch017-12/16/2004
1352In response to Neuroinvest I summarized my recent thoughts on the Dex Ph III triClarksterh-12/15/2004
1351Pharmos: The countdown begins Phase III clinical trial results for dexanabinolmidastouch017-12/9/2004
1350Study of safety issues surrounding the medical use of cannabis has just been laumidastouch017-12/9/2004
1349Yesterday The Globes published a 3 page article about PARS, the official translamidastouch017-12/8/2004
1348Pharmos officers selling options a month before test results 05.12.2004 | 11rjk01-12/5/2004
1347sorry, i did not mean it that way. I did not assumed you were of a diff opinion rjk01-12/5/2004
1346I put together a spreadsheet based upon a moderately extensive literature searchClarksterh-12/5/2004
1345I don't understand how we are assuming "opposites"--just differentNeuroInvestment-12/5/2004
1344<b>But I firmly believe it does not reflect a leak--though it does providerjk01-12/5/2004
1343Aviv sold around 12% of his holdings. It was clearly a hedge against unexpected NeuroInvestment-12/5/2004
1342I was away at copper Mt. on a ski trip, came back to this. Any comments? Pharmosrjk01-12/5/2004
1341Good to see you posting here. I used to enjoy some of your messages on the YahooJorgen Jensen-12/3/2004
1340Despite the fact that the drug treated groups contained a larger number of more Gabe Fernandez-12/3/2004
1339gfp - <i>another explanation might involve the fact that GOSE is a finer sClarksterh-12/3/2004
1338Clark, Concerning your point about the seemingly low 26% GOSE 7-8 grouping in gfp927z-12/3/2004
1337<<I'd agree, but Pharmos says in their published paper "dexanabinNeuroInvestment-12/2/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News